Kos Pharmaceuticals clinical trials
Formerly part of Abbott, Jan 1, 2013 · source ↗
The registry lists 5 studies whose lead sponsor is Kos Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 2, 2006.
Before and after it left Abbott
- First submitted before Kos Pharmaceuticals left Abbott
- 5
- First submitted after Kos Pharmaceuticals left Abbott
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Kos Pharmaceuticals5 studies
Something wrong with this grouping? Tell us on the Abbott page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Abbott studies →
- The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPICCompletedNCT00071266Phase 3
Sponsor listed in the registry: Kos Pharmaceuticals · First submitted before Kos Pharmaceuticals left Abbott
- Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELLCompletedNCT00079638Phase 4
Sponsor listed in the registry: Kos Pharmaceuticals · First submitted before Kos Pharmaceuticals left Abbott
- Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)CompletedNCT00080275Phase 3
Sponsor listed in the registry: Kos Pharmaceuticals · First submitted before Kos Pharmaceuticals left Abbott
- Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent ClaudicationCompletedNCT00062556Phase 3
Sponsor listed in the registry: Kos Pharmaceuticals · First submitted before Kos Pharmaceuticals left Abbott
- Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOASTCompletedNCT00082251Phase 3
Sponsor listed in the registry: Kos Pharmaceuticals · First submitted before Kos Pharmaceuticals left Abbott